MicroRNA-206 predicts raised fetal growth retardation risk through the interaction with vascular endothelial growth factor in pregnancies.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
entrez:
13
2
2020
pubmed:
13
2
2020
medline:
27
2
2020
Statut:
ppublish
Résumé
This study aimed to investigate the correlation of microRNA (miR)-206, vascular endothelial growth factor (VEGF) and miR-206/VEGF axis at different gestational ages with fetal growth retardation (FGR) risk in pregnancies.Eight hundred twenty pregnancies were consecutively recruited and their plasma samples were collected at early pregnancy (gestational age ≤ 13 weeks), middle pregnancy (gestational age: 14-27 weeks) and late pregnancy (gestational age ≥ 28 weeks), respectively. miR-206 expression and VEGF level in plasma were detected by quantitative polymerase chain reaction and enzyme-linked immunosorbent assay respectively. FGR was diagnosed based on the actual birth weight of fetus.miR-206 expression was negatively correlated with VEGF expression at early pregnancy, middle pregnancy and late pregnancy. Besides, miR-206 expression and miR-206/VEGF axis were elevated, but VEGF expression was decreased along with the increased gestational age. There were 74 FGR pregnancies and 746 non-FGR pregnancies. And both miR-206 expression and miR-206/VEGF axis were increased, but VEGF expression was reduced in FGR group compared to non-FGR group at early pregnancy, middle pregnancy and late pregnancy. Additionally, miR-206, VEGF and miR-206/VEGF axis at middle pregnancy and late pregnancy all showed good predictive values for FGR risk, and these indexes at late pregnancy exhibited the numerically highest predictive value for FGR risk. Furthermore, compared to miR-206 or VEGF alone, miR-206/VEGF axis presented with numerically higher predictive value for FGR risk.miR-206 predicts raised FGR risk through the interaction with VEGF in pregnancies, and it may serve as a novel biomarker for FGR prevention.
Identifiants
pubmed: 32049790
doi: 10.1097/MD.0000000000018897
pii: 00005792-202002140-00016
pmc: PMC7035023
doi:
Substances chimiques
3' Untranslated Regions
0
MIRN206 microRNA, human
0
MicroRNAs
0
VEGFA protein, human
0
Vascular Endothelial Growth Factor A
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e18897Références
Cottrell E, Tropea T, Ormesher L, et al. Dietary interventions for fetal growth restriction—therapeutic potential of dietary nitrate supplementation in pregnancy. J Physiol 2017;595:5095–102.
Bamfo JE, Odibo AO. Diagnosis and management of fetal growth restriction. J Pregnancy 2011;2011:640715.
Kesavan K, Devaskar SU. Intrauterine growth restriction: postnatal monitoring and outcomes. Pediatr Clin North Am 2019;66:403–23.
Rosenberg A. The IUGR newborn. Semin Perinatol 2008;32:219–24.
Leite DFB, Morillon AC, Melo Junior EF, et al. Metabolomics for predicting fetal growth restriction: protocol for a systematic review and meta-analysis. BMJ Open 2018;8:e022743.
Akehurst C, Small HY, Sharafetdinova L, et al. Differential expression of microRNA-206 and its target genes in preeclampsia. J Hypertens 2015;33:2068–74.
Fu G, Brkic J, Hayder H, et al. MicroRNAs in human placental development and pregnancy complications. Int J Mol Sci 2013;14:5519–44.
Hu J, Kong M, Ye Y, et al. Serum miR-206 and other muscle-specific microRNAs as non-invasive biomarkers for Duchenne muscular dystrophy. J Neurochem 2014;129:877–83.
Wang M, Ji Y, Cai S, et al. MiR-206 suppresses the progression of coronary artery disease by modulating Vascular Endothelial Growth Factor (VEGF) expression. Med Sci Monit 2016;22:5011–20.
Zhang T, Liu M, Wang C, et al. Down-regulation of MiR-206 promotes proliferation and invasion of laryngeal cancer by regulating VEGF expression. Anticancer Res 2011;31:3859–63.
Liang Z, Bian X, Shim H. Downregulation of microRNA-206 promotes invasion and angiogenesis of triple negative breast cancer. Biochem Biophys Res Commun 2016;477:461–6.
Su MT, Tsai PY, Tsai HL, et al. miR-346 and miR-582-3p-regulated EG-VEGF expression and trophoblast invasion via matrix metalloproteinases 2 and 9. Biofactors 2017;43:210–9.
Murthi P, Brouillet S, Pratt A, et al. An EG-VEGF-dependent decrease in homeobox gene NKX3.1 contributes to cytotrophoblast dysfunction: a possible mechanism in human fetal growth restriction. Mol Med 2015;21:645–56.
Tang Y, Ye W, Liu X, et al. VEGF and sFLT-1 in serum of PIH patients and effects on the foetus. Exp Ther Med 2019;17:2123–8.
Voller SB, Chock S, Ernst LM, et al. Cord blood biomarkers of vascular endothelial growth (VEGF and sFlt-1) and postnatal growth: a preterm birth cohort study. Early Hum Dev 2014;90:195–200.
Xu F, Xu S, Shao X, et al. Deficiency of calcium and microelements predict the risk of fetal growth restriction. Int J Clin Exp Med 2017;10:7491–9.
Falcone G, Perfetti A, Cardinali B, et al. Noncoding RNAs: emerging players in muscular dystrophies. Biomed Res Int 2014;2014:503634.
Chen Y, Yang YR, Fan XL, et al. miR-206 inhibits osteogenic differentiation of bone marrow mesenchymal stem cells by targetting glutaminase. Biosci Rep 2019;39: doi: 10.1042/BSR20181108.
doi: 10.1042/BSR20181108
Winbanks CE, Beyer C, Hagg A, et al. miR-206 represses hypertrophy of myogenic cells but not muscle fibers via inhibition of HDAC4. PLoS One 2013;8:e73589.
Xing Q, Shan Z, Gao Y, et al. Differential expression of MicroRNAs and miR-206-mediated downregulation of BDNF expression in the rat fetal brain following maternal hypothyroidism. Horm Metab Res 2018;50:696–703.
Christian LM, Mitchell AM, Gillespie SL, et al. Serum brain-derived neurotrophic factor (BDNF) across pregnancy and postpartum: Associations with race, depressive symptoms, and low birth weight. Psychoneuroendocrinology 2016;74:69–76.
Valdes G, Erices R, Chacon C, et al. Angiogenic, hyperpermeability and vasodilator network in utero-placental units along pregnancy in the guinea-pig (Cavia porcellus). Reprod Biol Endocrinol 2008;6:13.
Babischkin JS, Aberdeen GW, Lindner JR, et al. Vascular endothelial growth factor delivery to placental basal plate promotes uterine artery remodeling in the primate. Endocrinology 2019;160:1492–505.
Morita A, Nakahara T, Abe N, et al. Treatment of mid-pregnant mice with KRN633, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, induces abnormal retinal vascular patterning in their newborn pups. Birth Defects Res B Dev Reprod Toxicol 2014;101:293–9.
Patten IS, Rana S, Shahul S, et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature 2012;485:333–8.